Eikon pulls in $351M as lead drugs begins Phase III journey

Eikon Therapeutics Secures $350.7 Million Series D to Advance Cancer Drug Pipeline

Eikon Therapeutics, a pivotal-stage biotechnology company, has raised $350.7 million in a Series D financing round to support its clinical-stage programs and future pipeline development1 4 7. This significant funding brings Eikon's total capital raised since its founding in 2019 to over $1.1 billion1 7.

## Key Highlights:

- Lead Asset:
EIK1001, a systemically administered co-agonist of toll-like receptors 7 and 8, is currently in Phase III trials for advanced melanoma4 7.

- Clinical Pipeline:

* - EIK1003:*
A highly selective PARP1 inhibitor in Phase 1 evaluation for breast, ovarian, prostate, and pancreatic cancers1 7.

* - EIK1004:*
A central nervous system-penetrant PARP1-selective inhibitor poised to enter Phase 1 testing for brain cancers1 7.

- Early-Stage Pipeline:
Includes two androgen receptor antagonists and an internally derived WRN inhibitor (EIK1005) for potential treatment of MSI-high and other DNA repair-deficient cancers7.

## Funding Details:

The Series D round was led by existing investors with participation from new investors7.
The investment syndicate includes top mutual funds, sovereign wealth funds, and healthcare and technology-focused venture firms7.

- Notable investors:
Lux Capital, Alexandria Venture Investments, AME Cloud Ventures, The Column Group, Foresite Capital, and T. Rowe Price Associates, among others7.

## Company Background:

Eikon Therapeutics integrates advanced engineering with cutting-edge molecular and cell biology to accelerate drug discovery and development7. The company's proprietary single-molecule tracking technology allows for uncovering biological processes in living cells with unprecedented precision7.

## Future Plans:

CEO Roger M. Perlmutter stated that the funding will support building a fully-integrated, 21st-century biotechnology company leveraging advanced computing and data sciences7. Eikon's clinical studies are currently operating in 28 countries across 5 continents7.

This substantial funding round positions Eikon Therapeutics as a significant player in the biotech industry, with a focus on developing innovative cancer therapies and expanding its research and development capabilities.